Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,347 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder
Interventions
GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more
Conditions
Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Oak Lawn, Illinois
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Conditions
Inflammation, Crohn's Disease
Interventions
NNC0114-0006, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
Tucson, Arizona • Little Rock, Arkansas • Laguna Hills, California + 5 more
Conditions
Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions
RSLV-132, Sodium Chloride 0.9%
Drug
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more
Conditions
TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 9 more
Conditions
Acute Heart Failure With Reduced Ejection Fraction
Interventions
APD418, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more
Conditions
COVID-19
Interventions
HB-adMSCs, Placebos
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sugar Land, Texas
Completed Phase 1Phase 2 Interventional Results available

Intravenous Exenatide (Byetta) During Surgery

NCT00882050
Conditions
Euglycemia, Hypoglycemia, Hyperglycemia
Interventions
Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Conditions
Post-Operative Ileus (POI)
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
VB11, Surgery, Placebo, Bevacizumab
Drug · Procedure · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

NCT06933381
Conditions
Reducing Pain With Nexplanon Implant Insertion
Interventions
Vapocoolant spray, Placebo
Device · Other
Lead sponsor
Queen's Medical Center
Other
Eligibility
14 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Honolulu, Hawaii • Waimea, Hawaii
Conditions
DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
Interventions
Placebo, AOC 1001
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
68
States / cities
Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more
Conditions
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Interventions
AMG 714, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • New York, New York
Active, not recruiting Phase 4 Interventional

Muscle Impact of Treating Osteoporosis

NCT05666310
Conditions
Sarcopenia, Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo
Drug · Other
Lead sponsor
Nami Safai Haeri
Other
Eligibility
65 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Episodic Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more
Conditions
Hereditary Angioedema
Interventions
NTLA-2002, Normal Saline IV Administration
Biological
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more
Conditions
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions
Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Albumin Infusion
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Targeting ER Stress in Vascular Dysfunction

NCT04001647
Conditions
Vasodilation, Arterial Stiffness
Interventions
Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Pain
Interventions
Ropivacaine, dex, Bupivacaine, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Cleveland, Ohio • Euclid, Ohio